483
Celgene CorporationCelgene Corporation – FDA 483, Aug 4, 2015
Record Details
An FDA inspection of Celgene Corporation in Berkeley Heights, NJ, revealed significant deficiencies in adverse drug experience reporting. The firm failed to submit numerous serious and unexpected adverse drug experience reports within the required 15 calendar days. This included over 1400 late reports for products like Revlimid, Abraxane, Pomalyst, and Otezla between January 2014 and July 2015.
View Company Profile
ID · f7303fd4-02a8-414f-9cd8-5e8a97f8bfd2
Other documents for Celgene Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.